Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: A pilot study

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 1, 2011, Pages 13-22

  Annibale, B ^a   Maconi, G ^b   Lahner, E ^a   De Giorgi, F ^c   Cuomo, R ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Diverticulum; Lactobacillus; Probiotics; Synbiotics

Indexed keywords

GENEFILUS F19; LACTOBACILLUS PARACASEI F19; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOATING; BLOOD CELL COUNT; CLINICAL ARTICLE; CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DIVERTICULOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH FIBER DIET; HUMAN; LACTOBACILLUS PARACASEI; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PROTEIN ELECTROPHORESIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SHORT FORM 36; SIDE EFFECT; VISUAL ANALOG SCALE;

ABDOMINAL PAIN; AGED; DIETARY FIBER; DIVERTICULITIS; DIVERTICULUM; FEMALE; FLATULENCE; HUMANS; LACTOBACILLUS CASEI; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; TREATMENT OUTCOME;

EID: 79957631319     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parra-Blanco A. Colonic diverticular disease: Pathophysiology and clinical picture. Digestion 2006;73 (Suppl 1):47-57.
2. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004;363:631-9.
3. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008;103:1550-6.
4. Floch MH. Symptom severity and disease activity indices for diverticulitis. J Clin Gastroenterol 2008;42:1135-6.
5. Di Mario F, Comparato G, Fanigliulo L, Aragona G, Cavallaro LG, Cavestro GM et al. Use of mesalazine in diverticular disease. J Clin Gastroenterol 2006;40(Suppl 3): S155-9. [PMID: 16885700 DOI:]
6. Ludeman L, Warren BF, Shepherd NA. The pathology of diverticular disease. Best Pract Res Clin Gastroenterol 2002; 16: 543-62.
7. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:3110-21.
8. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 2004;10:PI 70-3.
9. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 2002;34:510-5. (Pubitemid 34830693)
10. Gatta L, Vakil N, Vaira D, Pilotto A, Curlo M, Comparato G et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease J Clin Gastroenterol 2010;44:113-9
11. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008;103:1557-67. (Pubitemid 351813918)
12. Moayyedi P, Ford AC, Talley NJ, Cremonini F, FoxxOrenstein A, Brandt L et at. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32.
13. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease. Eur J Gastroenterol Hepatol 2003;15:313-5. (Pubitemid 36337852)
14. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006;40:312-6. (Pubitemid 44309523)
15. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic misture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal 2007;22:1103-8. (Pubitemid 47500254)
16. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008;55:916-20. (Pubitemid 351975955)
17. rd edition. McLean, VA: Degnon Associates Inc; 2006. p. 1-29.
18. Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol and Hepatol 2003;15:1005-10. (Pubitemid 37094301)
19. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36® health profiles and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33(Suppl. 4): AS264-AS279.
20. Sanders ME. Considerations for use of probiotic bacteria to modulate human health. J Nutr 2000;130(2S Suppl):384S-390S.
21. Sullivan A, Nord CE. Probiotics and gastrointestinal disease. J Intern Med 2005;257:78-92.
22. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Practice Res Clin Gastroenterol 2003;17:755-73.
23. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptoms responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51. (Pubitemid 40585355)
24. Sullivan Å, Nord CE, Evengård B. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr J. 2009;8:4.
25. rd Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29-34.
26. Corsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004;99:1152-9. (Pubitemid 38917823)
27. Cremonini F, Talley NJ. Review article: the overlap between functional dyspepsia and irritable bowel syndrome - a tale of one or two disorders? Aliment Pharmacol Ther 2004;20:40-9.